Dawei W. Rong

Key Laboratory Of Liver Transplantation, NHC Key Laboratory Of Living Donor Liver Transplantation
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Erratum: [Corrigendum] Overexpression of lncRNA AFAP1-AS1 promotes cell proliferation and invasion in gastric cancer.

Erratum: [Corrigendum] Overexpression of lncRNA AFAP1-AS1 promotes cell proliferation and invasion in gastric cancer.

Journal: Oncology letters

Published: July 01, 2026

Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.

Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.

Journal: Journal of gastrointestinal oncology

Published: July 17, 2023

Retraction Note: CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p.

Retraction Note: CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p.

Journal: Molecular cancer

Published: January 16, 2023

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.

Journal: Journal for immunotherapy of cancer

Published: January 13, 2023

CHSY1 promotes CD8+ T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening.

CHSY1 promotes CD8+ T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 07, 2023

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: December 01, 2022

Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.

Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.

Journal: Redox biology

Published: July 07, 2022

Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma

Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma

Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]

Published: July 01, 2022

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.

CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.

Journal: Journal of experimental & clinical cancer research : CR

Published: June 27, 2022

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma.

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma.

Journal: Cancer cell international

Published: May 23, 2022

Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Journal: International journal of biological sciences

Published: April 13, 2022

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.

Journal: Frontiers in immunology

Published: February 15, 2022

Showing 1-12 of 40

Last Updated: 09/26/2026